138 / 1851
Neoadjuvant therapy
•
Pro:
–
Increasing rate of BCT
–
Pathological complete
response
–
Drug develomment
•
Contras:
–
Low rate of pCR (ER+)
–
Select subgroups
–
Implication for surgeons and
radiation oncologists
Newly diagnosed tumor
Preferred option in some subtypes (triple negative ed HER2
positive)
Curative intent
Residual tumor
THERAPY
15